# Liraglutide and Beta-Cell Function: RISE | GLP1Nerds Canonical: https://glp1nerds.com/research/liraglutide-beta-cell-rise/ Published: 2026-10-25 Updated: 2026-10-25 RISE found on-treatment improvements with liraglutide plus metformin, but no durable beta-cell benefit three months after withdrawal in its adult study. [Research](https://glp1nerds.com/research/)/Medications Medications # Liraglutide, beta-cell function and withdrawal: RISE RISE found on-treatment improvements with liraglutide plus metformin, but no durable beta-cell benefit three months after withdrawal in its adult study. OC[Owen Calder](https://glp1nerds.com/authors/owen-calder/)Founding Editor · Updated October 2026 Editorial analysis · Not a clinical consultation ![Three qualitative study phases identify on-treatment measurement, withdrawal and off-treatment follow-up.](https://glp1nerds.com/assets/editorial/liraglutide-beta-cell-rise.svg) Conceptual study-phase diagram. It contains no data curve or claim that beta-cell changes persist after treatment. ## What to know - RISE found on-treatment improvements with liraglutide plus metformin, but no durable beta-cell benefit three months after withdrawal in its adult study. - Population, comparison and follow-up determine what the finding can establish. - A study average is not an individualized outcome prediction. ## The trial asked about persistence after treatment RISE was designed around a demanding question: could early drug treatment improve beta-cell function in a way that lasted after treatment stopped? That is different from asking whether glucose or weight improves while a medicine is taken. In the adult medication study, active treatments produced on-treatment improvements, particularly the liraglutide-plus-metformin strategy. The benefit did not persist on the primary beta-cell assessment three months after withdrawal. This is an important boundary for claims about restoring pancreatic function. An effect while a drug is present is not automatically evidence that a limited course permanently changes the underlying disease process.[\[1\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-1) [\[2\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-2) For the related decision, read [the connected evidence](https://glp1nerds.com/research/liraglutide-scale-weight-loss/). ## The adult medication population was specific The study included 267 adults, most with impaired glucose tolerance and the remainder with recently diagnosed, treatment-naive type 2 diabetes. Established, longstanding diabetes was not the study population. Participants were assigned to metformin alone, glargine followed by metformin, liraglutide plus metformin, or placebo. Treatment lasted 12 months, followed by three months off therapy. Because liraglutide was combined with metformin, the result should not be described as a liraglutide-only trial. Similarly, the glargine strategy involved a sequence rather than continuous insulin for the entire period. Naming the actual strategies prevents the headline from becoming more general than the experiment.[\[1\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-1) ## A clamp is not a scan counting beta cells Investigators assessed beta-cell function with hyperglycemic clamp procedures at baseline, during treatment and after withdrawal. These controlled physiological tests examine how insulin secretion responds under defined glucose conditions, with insulin sensitivity taken into account. They do not directly count cells in the pancreas or show regeneration through an imaging result. That distinction matters because restoration language can imply a physical rebuilding claim the endpoint did not measure. A favorable functional response may be scientifically useful without demonstrating new beta-cell mass. Consumers should ask what was actually measured whenever a program uses biological repair language to describe a laboratory outcome.[\[1\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-1) [\[2\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-2) ## The primary outcome came after withdrawal The prespecified primary question concerned beta-cell function at month 15 compared with baseline, after three months off treatment. Liraglutide plus metformin produced notable improvements while treatment continued, but these did not establish a lasting advantage after withdrawal. Reading only the month-12 response would therefore answer a different question from the study's main durability objective. The post-treatment assessment is not an optional disappointing detail to omit. It was integral to testing whether the interventions changed the course of the physiological problem beyond their active use. That design makes RISE especially relevant when interpreting promises of a short restorative course.[\[1\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-1) [\[2\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-2) For the related decision, read [our support-model comparison](https://glp1nerds.com/compare/clinic-vs-pharmacy-access/). ## Glucose and weight improvement still have meaning The absence of a durable off-treatment beta-cell result does not erase the observed improvements during therapy. It also does not mean that continuing treatment is pointless or that a person responding to medication has failed to achieve a real benefit. The study separated active treatment effects from persistence after stopping. Those can both be clinically relevant questions, but they need different evidence. A reader should avoid the opposite exaggerations of calling the treatment a permanent cure or declaring it ineffective because its effects did not remain after withdrawal. The useful interpretation preserves the period during which an outcome was measured.[\[1\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-1) ## Adult and youth findings should not be merged casually RISE also included youth studies, and a later analysis compared beta-cell responses across youth and adults. It reported important differences in the trajectory during treatment and after withdrawal. That does not turn the adult liraglutide result into pediatric evidence for the same regimen. The medication assignments were not identical across every RISE protocol. A careful article names which cohort and treatment strategy a claim comes from, rather than treating a shared study acronym as proof that every intervention was tested in every age group. This is particularly important when early diabetes is described as though age makes no difference.[\[3\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-3) ## The dose and product context remain clinical The RISE protocol used a liraglutide diabetes-treatment strategy with metformin. It should not be conflated with an obesity-dose liraglutide program or with newer semaglutide and tirzepatide products. Current Victoza labeling identifies a diabetes product with its own indications, contraindications and warnings. A trial of one molecule does not establish identical beta-cell durability for every member of a drug class. Nor can its protocol be used as a personal stopping schedule. Anyone considering a change needs a clinician to assess the actual diagnosis, current medicines, glucose measures and treatment goals.[\[2\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-2) [\[4\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-4) For the related decision, read [our 9Amhealth review](https://glp1nerds.com/reviews/9amhealth/). ## Three months off therapy is a defined window RISE's withdrawal period lets investigators test persistence over a specified interval. It does not establish every possible outcome over a decade or determine whether a different treatment duration would change the result. Those remain separate questions. At the same time, an untested possibility should not be used to override the observed negative durability result. The trial supports a bounded conclusion: this set of strategies, used for this period in these adults, did not produce the hoped-for lasting beta-cell improvement after withdrawal. That precision is more useful than either a universal failure claim or speculation that a longer course must work. ## What a commercial restoration claim would need A service claiming to restore beta-cell function should identify the actual intervention, population, physiological endpoint and off-treatment follow-up behind that statement. A lower HbA1c during medication use is not by itself evidence of durable restoration. Neither is an individual's testimonial sufficient to establish disease modification. A legitimate treatment program can discuss improvements without using a more permanent label than its evidence supports. For a buyer, this distinction helps separate the value of continuing appropriate care from a promise that a paid course will remove the need for future monitoring or medication. RISE gives a concrete example of why that boundary matters. ## The practical conclusion RISE supports recognizing the difference between improving a measure during treatment and sustaining that improvement after withdrawal. Liraglutide plus metformin performed well during active use in the adult medication study, but did not establish durable beta-cell benefit three months after stopping. That result is about the tested early-dysglycemia population and the specified strategies. Bring claims about remission, restoration or stopping medicine to the responsible clinician with the underlying endpoint visible. The study is not an instruction to stop treatment; it is a reason to ask what a proposed benefit actually means and how ongoing care will be assessed.[\[1\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-1) [\[2\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-2) [\[4\]](https://glp1nerds.com/research/liraglutide-beta-cell-rise/#reference-4) ## Read the evidence alongside the practical choice [the connected evidence](https://glp1nerds.com/research/liraglutide-scale-weight-loss/) [our support-model comparison](https://glp1nerds.com/compare/clinic-vs-pharmacy-access/) [our 9Amhealth review](https://glp1nerds.com/reviews/9amhealth/) ## Sources - [RISE Consortium. Adult medication withdrawal and beta-cell function trial (2019) (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/31178434/) - [NIDDK RISE Adult Medication study repository and protocol (opens in a new tab)](https://repository.niddk.nih.gov/study/268) - [RISE investigators. Differential beta-cell function after withdrawal in youth and adults (2021) (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/34274407/) - [Victoza current prescribing information (opens in a new tab)](https://www.novo-pi.com/victoza.pdf) Research describes groups and specific study conditions. Your medical history, symptoms and treatment decisions require advice from your own qualified clinician. ## Keep exploring. [Research library](https://glp1nerds.com/research/) Medications ### [Liraglutide for weight loss: what the SCALE trials establish](https://glp1nerds.com/research/liraglutide-scale-weight-loss/) Daily liraglutide improved average weight outcomes in SCALE, but starting treatment, maintaining prior loss and preventing diabetes are separate questions. Owen Calder Medications ### [Oral semaglutide vs liraglutide: PIONEER 4](https://glp1nerds.com/research/oral-semaglutide-liraglutide-pioneer4/) PIONEER 4 compared an oral semaglutide formulation with injected liraglutide in diabetes. Noninferiority, dose and analysis define its meaning. Owen Calder Medications ### [Semaglutide vs tirzepatide: what the direct trial answers](https://glp1nerds.com/research/semaglutide-vs-tirzepatide/) The strongest comparison concerns specific injectable doses, a defined population and 72 weeks of follow-up. Owen Calder